Tiga Therapeutics

Tiga Therapeutics is a Netherlands-based biotechnology company specializing in the development of a novel class of cancer immunotherapies using Immunoglobulin A (IgA) antibodies. Unlike traditional IgG-based therapies, Tiga's platform leverages the unique ability of IgA to potently activate neutrophils, the most abundant type of white blood cell, to eliminate tumor cells. The company's lead candidate, TIGA-01, is a best-in-class IgA antibody targeting HER2-positive solid tumors, designed to overcome resistance mechanisms associated with current treatments. By focusing on the myeloid lineage of the immune system, Tiga aims to provide new therapeutic options for patients with hard-to-treat cancers. The company is a spin-off from the University Medical Center Utrecht, built upon decades of research into IgA biology.